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Chapter 1 
Introduction 
 
 
1.1        Background 
 Apoptosis, or programmed cell death, plays an integral role during development, host 
defense against pathogens, and regulation of the immune system.  Apoptosis is a highly regulated 
and conserved pathway in multicellular organisms and is characterized by nuclear and 
cytoplasmic condensation followed by membrane blebbing and cellular fragmentation into 
vesicles called apoptotic bodies, which are then taken up and degraded by phagosomes [1].  
Unlike death by cellular injury, apoptosis does not cause inflammation or tissue damage.  In 
addition, cellular components from the dying cell can be reused [2].  Due to the importance of 
apoptosis in the maintenance of homeostasis in living organisms, defects in the apoptotic cascade 
can result in severe problems.  For example, deregulation of the apoptotic pathway due to 
increased apoptosis has been associated with degenerative diseases such as Alzheimer’s and 
Parkinson’s, while a failure to execute apoptosis is associated with inflammatory diseases and 
cancer [3] [4].  Chemotherapeutic drugs such as etoposide are used to kill cells by activating the 
apoptotic process [5].  Thus, understanding how to control the apoptotic pathway has been an 
attractive topic with the ultimate goal to provide novel treatments against disease based on the 
manipulation of cell death and survival. 
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1.2       Caspase family   
 The caspases are a conserved family of cysteine proteases that are essential for cells to 
undergo apoptosis.  The first caspase protein, ced-3, was initially cloned from C. elegans [6].  
Since then, caspases have also been found in both vertebrates and invertebrates.  To date, 12 
caspases have been found and cloned in humans (see Table 1) [7] [8].  They are all expressed as 
proenzymes and are composed of three subunits: an amino-terminal prodomain, a large subunit, 
and a small subunit [9].  They are activated upon cleavage of one of the domains followed by 
association of the small and large subunits into a heterodimer.   
 
Table 1: Members of the Caspase Family (in Humans) 
 Role Binding Domain Present 
Caspase-1 Inflammation CARD 
Caspase-4 Inflammation CARD 
Caspase-5 Inflammation CARD 
Caspase-2 Apoptosis: Initiator CARD 
Caspase-8 Apoptosis: Initiator DED 
Caspase-9 Apoptosis: Initiator CARD 
Caspase-10 Apoptosis: Initiator DED 
Caspase-12 Apoptosis: Initiator CARD 
Caspase-3 Apoptosis: Effector  
Caspase-6 Apoptosis: Effector  
Caspase-7 Apoptosis: Effector  
Caspase-14 Human keratinocyte 
differentiation [10] 
 
• CARD = Caspase activation and recruitment domain.  DED = Death effector domain 
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Caspase-1, caspase-4, and caspase-5 belong to a family of inflammatory caspases that are 
involved in cytokine maturation [11] [12].  There are two classes of caspases important to 
apoptosis: initiator caspases and effector caspases.  Initiator caspases receive signals and cleave 
effector caspases, thereby activating them.  The effector caspases, in turn, activate the pathways 
that result in the changes characteristic of cell death.    
 Apoptosis can be activated in the cell through the extrinsic and intrinsic pathways (Fig. 
1).  In the extrinsic pathway, death receptors of the TNF family are activated by binding to death 
ligands.  In turn, the activator caspase-8 is recruited to the death-inducing signaling complex 
(DISC) by binding to the adaptor protein FADD via the death effector domain [13].  When 
bound to the DISC, procaspase-8 molecules are in close proximity and activate each other by 
auto-proteolysis [14].  Caspase-8 cleaves and activates effector caspases such as caspase-3, 
resulting in cell death [15]. 
In the intrinsic pathway, also known as the mitochondrial death pathway, death signals 
resulting from DNA damage, defective cell cycle, or cell stress lead to cytochrome c release 
from mitochondria [16].  After released, cytochrome c binds to the Apaf-1 adaptor protein and 
facilitates the formation of the apoptosome, which binds to and activates caspase-9.  Activated 
caspase-9 then cleaves and activates the downstream effector caspases to activate cell death [17].  
Both the extrinsic and intrinsic pathways converge and result in cleavage and activation of the 
downstream effector caspases. 
Initiator caspases generally have long prodomains consisting of protein-protein 
interaction domains important for directing the caspases for activation [18].  The initiator 
caspases, caspase-2, caspase-9, and caspase-12 contain a caspase activation and recruitment 
domain (CARD) while caspase-8 and caspase-10 contain death effector domains (DED) [7].    
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Figure 1: Pathways to Activate Caspase-3 
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These domains are found on the amino terminal of the proteins and bind to similar motifs 
in adaptor proteins.  Activation of caspase-8 requires association with its cofactor, FADD 
through the DED while caspase-9 activation requires it to complex with APAF though the 
CARD domain [19]. Effector caspases such as caspase-3, caspase-6, and caspase-7, in contrast, 
have short prodomains (~30 amino acids) and the function of this domain is so far unknown [20].  
They require cleavage by the initiator caspases for activation and are known to cleave a small 
subset of substrates at specific sites, helping to dismantle the cell into apoptotic bodies. 
 
1.3       Caspase-3 
 Caspase-3 is a key mediator of cell death.  It is an effector caspase that after being 
activated by initiator caspases proceeds to cleave essential cellular machinery, resulting in the 
morphological changes characteristic of cell death.  Caspase-3 was initially described as a 
protease resembling the interleukin 1-β-converting enzyme family that is involved in initiating 
apoptosis.  The protein, initially named prICE, was found to be play an important role in 
initiating apoptosis by cleaving the nuclear enzyme poly(ADP-ribose) polymerase (PARP) [21].  
The protein was also named CPP32, yama, or apopain by other investigators [22] [23].  Caspase-
3 has significant homology to the C. elegans cell death protein ced-3 and over expression in SF9 
insect cells resulted in increased apoptosis, indicating its major role in cell death [24].  Caspase-3 
has also been shown to be important for apoptosis during mouse development [25].  The 
proenzyme consists of 3 domains: prodomain, p17, and p12.  The crystal structure for only the 
p17 and p12 domains has been determined  [26]. Like other members of the caspase family, 
caspase-3 exists as an inactive zymogen and requires a proteolytic cleavage by an initiator 
caspase.  Activation of caspase-3 requires two steps (Fig. 2).  The first cleavage occurs between 
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Figure 2: Caspase-3 activation 
the p12 and p17 domains at Asp175 and is catalyzed by the activated initiator caspases [27].  The 
second cleavage occurs between the p17 and pro-domains and is autocatalytic.  After the second 
cleavage, the p17 and p12 domains rearrange 
into the active tetramer [28].  It has been shown 
that removal of the prodomain from the 
caspase-3 proenzyme results in spontaneous 
proteolytic activation of the enzyme, indicating 
that the prodomain serves as a  repressor of 
caspase-3 activation [29] [30].  However, the 
regulation of the autocatalytic cleavage remains 
unknown.  The active caspase-3 tetramer is 
responsible for cleavage of essential proteins.  
The caspase-3 cleavage consensus  sequence is 
Asp-Glu-Val-Asp (DEVD), with the two aspartic 
acids being absolutely required for cleavage [31].  The function of caspase-3 cleavage is to either 
activate or inhibit the activity of its cellular targets, promoting the formation of apoptotic bodies 
[32].  Examples of substrates are PARP, α-fodrin, gelsolin, nuclear lamins, and focal adhesion 
kinase [33] [34] [35].  The active form of caspase-3 also cleaves and activates DNA 
fragmentation factor (DFF) [36].  The cleavage of these proteins results in the characteristic 
features of programmed cell death: cell shrinkage, nuclear fragmentation, and chromatin 
degradation.   
Caspase-3 has been widely studied because it is central to the control of apoptosis. MCF-
7 cancer cells have lost their endogenous caspase-3 due to a 47 base pair deletion within exon 3 
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of the caspase-3 gene, causing them to be resistant to apoptosis induced by chemotherapy [34] 
[37] [38].  In addition, caspase-3 deficient mice tend to die prematurely and show decreased 
apoptosis during brain development [39]. Targeting the caspase-3 pathway has been suggested as 
an approach to prevent many of the long-term neurological deficits after acute traumatic injury to 
the spinal cord, though the question remains on how to effectively target the pathway [40].  
Interestingly though, high levels of caspase-3 have been observed in certain human tumor cell 
lines, indicating that not only caspase-3 levels, but also regulatory mechanisms play an important 
role in the activation of casapse-3 and the apoptotic cascade [41]. Thus understanding the 
molecular mechanisms that regulate caspase-3 are paramount to gaining better knowledge of the 
basic mechanisms that regulate cell death and to improving current anti-cancer and anti-
inflammatory therapies.   
 The goal of this study is to determine how caspase-3 activation and activity is regulated.  
Elucidating the pathways and interactions that result in apoptosis can help lead to novel 
mechanisms of combating uncontrollable cell proliferation or degenerative diseases.  
  
1.4        Regulation of caspase-3  
Caspase-3 activation is highly regulated by protein-protein interactions and 
posttranslational modifications such as ubiquitination and phosphorylation.  The activation of 
caspases is regulated by many different protein families.  One family of proteins, the Bcl-2 
family, works to indirectly regulate apoptosis through regulating the release of cytochrome c 
from the mitochondria during the activation of the intrinsic pathway. The family is composed of 
pro-apoptotic (Bad, Bim, bax, etc..) and anti-apoptotic (Bcl-2, Bcl-XL, etc ) proteins [42].  Bcl-2 
inhibits the release of cytochrome c while  BAX promotes its release [43] [44].  Once activated 
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though, caspase-3 cleaves Bcl-2, further promoting the release of cytochrome c [32].  Another 
family of proteins, the Inhibitors of Apoptosis (IAP) are also important in down regulating 
caspase activity.  Survivin, a member of the family, has been shown to be a direct inhibitor of 
caspase-3 and caspase-7 by tightly binding to the caspases and sequestering them in inhibited 
states [45].  Another member of the family, X-linked inhibitor protein (XIAP) has also been 
shown to inhibit caspase-3 and caspase-7 via binding of the BIR domain [46] [47].  The small 
subunit N-terminus of caspase-3 binds to a groove in the BIR2 domain across two biologically 
functional units, with binding of one caspase-3 subunit to the BIR2 domain inhibiting the 
catalytic site of the adjacent casapse-3 molecule [48] [49].  It has also been demonstrated that the 
RING domain of XIAP enables the protein to decrease caspase activity by ubiquitination of 
selected caspases, such as caspase-3 and caspase-7, promoting their degradation via the 
proteosome [50].  
Caspases have also been demonstrated to be regulated by posttranslational modifications 
such as phosphorylation.  Phosphorylation is a well known mechanism for protein regulation that 
involves a transfer of a phosphate group by a kinase to an amino acid containing an R group with 
a free hydroxyl group in the substrate, either activating or inhibiting the molecule.  Kinases are 
very important in cancer studies since there are up to 518 kinase proteins in humans and 244 of 
them map to disease loci or cancer mutations [51]. Bid, a member of the Bcl-2 family, can be 
phosphorylated by casein kinase I and II, inhibiting its cleavage by caspase-8 and delaying Fas-
mediated apoptosis [52].  Caspase-9 can be phosphorylated at Ser196 by the anti-apoptotic 
kinase Akt, decreasing cytochrome c-induced processing of procaspase-9 and inhibiting its 
protease activity [53].  Caspase-9 activity is also inhibited by a phosphorylation at Thr125 by the 
ERK- mitogen activated protein kinase [54].  Phosphorylation of caspase-8 at Ser364 and 
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phosphorylation of caspase-3 at Ser150 by p38- mitogen activated protein kinase (MAPK) are 
known to inhibit the activity of those caspases [55] [56]. The majority of known phosphorylation 
reactions for posttranslational caspase modifications are inhibitory.    
Our group demonstrated that caspase-3 apoptotic activity is regulated by its direct 
association with protein kinase C δ (PKC δ) and heath shock protein 27 (Hsp27).  We showed 
that Hsp27 associates with caspase-3 in vivo and directly interacts with the amino terminal 
prodomain of caspase-3, inhibiting the second autocatalytic cleavage needed for activation [57].   
We found that the serine-threonine kinase, PKCδ, associates and phosphorylates caspase-
3 in vivo [58].  Protein kinase C  is a family of protein kinases that play an important role in 
regulating different cellular responses in multiple signaling pathways, including responses 
involving contraction, hypertrophy, membrane permeability, and apoptosis [59]. The protein 
kinase C family is classified into 3 groups based upon the presence or absence of motifs that bind 
to specific cofactors required for optimal activity: conventional and novel PCK family members 
bind to diacylglycerol (DAG) to stimulate kinase activity, with conventional PKC’s also 
requiring Ca+2, while atypical PKC’s do not interact with DAG [60].   
PKCδ belongs to the novel protein kinase C group and is involved in the apoptotic 
pathway. It has been previously shown that active caspase-3 cleaves PKCδ to a 40-kda fragment, 
resulting in a 9 fold increase in PKCδ activity [61].  PKCδ translocation to the nucleus following 
activation by caspase-3 is required for apoptosis to occur [62].  The activated PKCδ has been 
implicated as an apoptotic lamin kinase, providing a further mechanism for its pro-apoptotic 
abilities [63].   Over-expression of PKCδ in certain cell lines has been associated with an 
increase of apoptosis [61] [64] [65].  Conversely, PKCδ knockout mice are defective in 
mitochondrial-dependent apoptosis [66].  In addition, it has been shown that removal of PKCδ 
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by immunoprecipitation or silencing with rottlerin reduces DNA fragmentation and delays 
neutrophil apoptosis respectively [67].  Our lab had shown that caspase-3 interacts with PKCδ 
and that PKCδ-dependent phosphorylation of caspase-3 results in an increase in its apoptotic 
ability [58].  This is particularly interesting since most other phosphorylations of caspases cause 
a decrease in their apoptotic ability.  The molecular mechanisms of the PKCδ-dependent 
phosphorylation of caspase-3 remain an intriguing yet unknown area of study. 
  To further investigate the role of the phosphorylation of caspase-3, the objective of this 
study was to map the phosphorylation sites in caspase-3 and characterize their role in apoptosis.  
We identified seven potential phospho-sites using a combination of in silico bioinformatics and 
mass spectrometry approaches.  Single and multi point mutations were generated using site-
directed mutagenesis.  Mutations of specific sites to aspartic acid were done to mimic a 
phosphorylated molecule while mutations of specific sites to alanine or glycine were done to 
mimic a lack of phosphorylation.  In addition, clones were made that incorporated only specific 
domains, such as prop17, which lacked the p12 C-terminal domain.  The mutant caspases were 
used for both in vivo and in vitro analyses in order to determine the effects of the mutations on 
caspase-3 activity.  Our results detail a cascading mechanism for caspase-3 activation in response 
to PKCδ-dependent phosphorylation.  We have found that the Ser12 on caspase-3 is required for 
PKCδ-dependent phosphorylation and that phosphorylation of the site precedes the rest of the 
phosphorylations. Identification of the phosphorylation sites provide knowledge about the 
mechanisms responsible for the regulation of caspase-3 activity and could serve as a mechanism 
to control cell death and cell survival. 
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Chapter 2 
Materials and Methods 
 
 
2.1      Bacterial cultures and DNA purification 
Bacteria cells were cultured in 3 ml of LB media containing the appropriate antibiotic for 
plasmid selection at 37oC shaking at 200 rpm for 14 h.  Plasmid DNA was purified for screening 
using QIAprep Miniprep Kit following the manufacturer’s specifications (Qiagen, Valencia, 
CA).  Approximately four micrograms of plasmid DNA was digested with the restriction 
enzymes listed on Table 1 (New England Biolabs, Ipswich, MA), The plasmid DNA was added 
to 1X bovine serum albumin  (BSA), 1X appropriate NEB  buffer (New England Biolabs, 
Ipswich, MA),  0.3 µL of each restriction enzyme, and dH2O.  The digestion was allowed to 
proceed for 4 h at 37oC.  DNA loading buffer 6X (.25% bromophenol blue and 30% glycerol in 
H2O) was added to the digested product and the DNA was separated on a 1% agarose gel (1 g 
agarose/ 100 ml 1x Tris-Acetate EDTA Buffer) containing 0.2 µg/ml ethidium bromide to stain 
the DNA.  The 1 kb plus DNA ladder was loaded as well in order to verify if the digestion 
fragments were of the right size (Invitrogen, Carlsbad, CA).  The gel was run for 35 min at 90 V.  
DNA fragments were cut and purified utilizing the PureLink gel extraction kit (Invitrogen, 
Carlsbad, CA).  
 
2.2       Mutagenesis: 
 Caspase-3 mutants (Table 2) were created using Quick Change Single or Multi Site 
Directed Mutagenesis Kits (Stratagene, La Jolla, CA).  The caspase-3 gene (AB 468) was 
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amplified by PCR, utilizing 10 ng of template DNA, 125 ng each of the specific mutagenic 
primers needed to introduce the required mutation, 1X reaction buffer, 3 µL QuikSolution, 1 µL 
dNTP mix, and 2.5 Units of PfuUltra HF DNA polymerase.  The PCR reaction was carried out 
with 18-cycles of 50 seconds at 95°C, 50 second at 60°C, and 4 min at 68°C.  After 
amplification, the template plasmid DNA was eliminated by treatment with Dpn1 restriction 
enzyme for 2 h at 37oC.  1 μl of the digested DNA was then used to transform XL-10 Gold cells.  
Clones were then screened by restriction digestion, utilizing the restriction enzymes described on 
Table 1.  To screen for specific mutations, clones were selected, column purified, and sequenced 
(Macrogen, Korea).   
 
2.3       Transformation 
 Clones were amplified by transforming the DNA into competent cells.  Transformation of 
ligation products was performed by incubation of the ligation mixture with either 50 µl of One 
Shot Top10 cells or 30 µl of DH5α cells, on ice for 30 min.  The cells were heat shocked at 42o C 
for 45 seconds and then incubated on ice for 2 min.  250 µl SOC media (2% Tryptone, 0.5% 
Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose) was 
added to the transformation reaction, followed by incubation at 37° C shaking at 200 rpm for 1 h.  
The cells were then spread on LB-agar plates containing antibiotics specific for the vector and 
then grown for 14 h at 37oC.  Colonies obtained from the transformation were screened by 
cutting with the appropriate restriction enzymes (Table 1). 
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2.4         Cloning into pENTR/D-TOPO vector: 
 The pENTR/D-TOPO gateway system was utilized as an intermediate step that allowed 
the cloning of the mutant caspase-3 clones into pcDNA 4/His Max Xpress mammalian 
expression vector.  Caspase-3 mutants DNA were amplified by PCR to generate clones 
containing the appropriate restriction sites that were going to be used to clone them into the 
destination vector (Table 2). The PCR reactions were carried out with 30ng of DNA template, 25 
pmol forward and reverse primers, 3 mM MgCl2, 500 µM dNTP, 1x High Fidelity PCR Buffer 
(Invitrogen, Carlsbad, CA), 1 unit high fidelity Taq polymerase (Invitrogen, Carlsbad, CA), and 
dH2O.  The PCR was run with 30-cycles of 1 min at 95°C, 1 min at 58°C, and 1 min at 72°C.  
The PCR products were then ligated into the pENTR/D-TOPO vector by adding 2.5 ng of the 
PCR product was added to 0.5 µL of TOPO vector in the presence of 0.75 µL of salt solution and 
dH2O.  The ligated products were then transformed into Top10 one-shot cells and plated on LB 
agar containing 30 µg/ml kanamycin as a selective antibiotic.  Colonies were picked and 
screened by restriction digestion by cutting with BamHI and EcoRI (Table 1).   
 
2.5       Cloning into pcDNA 4/His Max Xpress vector:  
Positive caspase-3 inserts in the TOPO clones were selected to be cloned into the pcDNA 
4/His Max Xpress mammalian expression vector.  The DNA was digested with BamH1 and 
EcoR1 (New England Biolabs, Ipswich, MA), 1X BSA (New England Biolabs, Ipswich, MA), 
1X Buffer 3 (New England Biolabs, Ipswich, MA), and dH2O for 4 h at 37oC.  DNA loading 
buffer 6X was added to the digested product and the DNA was run on a 1% agarose gel for 1 h at 
90 V.  DNA fragments were cut and purified utilizing the PureLink gel extraction kit (Invitrogen, 
Carlsbad, CA).  Caspase-3 insert DNA and pcDNA 4/His Max Xpress vector were ligated on a 
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1:1 molar ratio with T4 ligase (Roche, Basel, Switzerland), 1X ligation buffer (Roche, Basel, 
Switzerland), and autoclaved H2O in a 5 µl volume.  The reaction was incubated for 14 h at 
16oC.  The ligated products were then transformed into DH5α cells and plated on Ampicillin 
plates.  Positive clones were screened by restriction digestion with BamH1 and EcoR1 enzymes. 
 
2.6       Protein purification 
One single colony was incubated for 14 h with constant shaking at 37ºC in 20 ml of 
Terrific Broth (TB) containing 20% glucose, in the presence of 100 µg/ml ampicillin and 30 
µg/ml kanamycin as selective antibiotics.  Cultures were transferred to 1 L of TB, containing 
selective antibiotics, and grown until they reached an optical density of 0.5 A550 at 37ºC.  Protein 
expression was induced by incubation with 1mM isopropyl 1-thio-β-D-galactopyranoside (IPTG, 
Gold Biotechnology, St. Louis, MO) for 30 min at 20ºC.  The cultures were harvested by 
centrifugation at 6,000 rpm for 5 min and then 2 grams of the pellet was lysed in 10 mL of 
sonication buffer (50 mM sodium phosphate, 150 mM sodium chloride, 1% Tween 20, 5 mM β-
mercaptoethanol, 0.1 mM PMSF, and 2 µg/ml CLAP). The lysates were then centrifuged for 10 
min at 12,000 rpm and the supernatant was incubated with 10 µg/ml RNAse (Invitrogen, 
Carlsbad, CA) and 5 µg/ml DNAse (Invitrogen, Carlsbad, CA)  The supernant was then filtered 
through miracloth (CalBiochem, San Diego, CA).  Supernants were then incubated with 250 µL 
of 50% slurry nickel beads (Ni+-NTA-superflow, Qiagen) for 90 min, on a rocking table at 4º C.  
The supernatant containing Ni+ beads were loaded into a column and eluted drop-wise at a speed 
of 1 ml/min.  The beads were rinsed twice with 5 ml sonication buffer followed by two rinses of 
5 ml wash with washing buffer (50 mM HEPES, 300 mM NaCl, 10% glycerol, 1% Tween 20, 1 
mM PMSF, and pH 7.4).  The protein was eluted with a discontinuous imidazole gradient (30 
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mM, 50 mM, and 100 mM imidazole dissolved in washing buffer).  Protein elutions were 
analyzed by SDS-PAGE on a 15% acrylamide gel and the proteins were visualized by 
Coomassie staining.  Purified proteins were dialyzed two times for 3 h at 4°C, with constant 
stirring, in caspase-3 reaction buffer (50 mM HEPES, pH 7.4, 50 mM NaCl, 10% sucrose, 0.1 
mM PMSF, and 1 mM DTT) in a 1:500 dilution.  Dialyzed proteins were snap-frozen in liquid 
nitrogen and stored in -80ºC.  Samples were analyzed by SDS-PAGE and visualized by 
Coomassie staining. 
 
2.7       Cell culture and transfection 
 HeLa cells were grown at 37°C in a modified atmosphere of 95% air and 5% CO2 in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% heat inactivated fetal 
bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin (P/S; BioWhittaker, 
Walkersville, MD).  To begin, 8 x 106 cells were transfected with Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) utilizing 8 µg of caspase-3-WT or caspase-3-mutant DNA in the 
pcDNA 4/His Max Xpress vector (See Appendix: Table 2 for clones and codes).  The DNA was 
added to DMEM solution to a total volume of 400 µl (set 1).  20 µl Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) and 380 µl DMEM solution was added to a total volume of 400 µl 
(set 2).  The reactions were incubated separately for 5 min.  Sets 1 and 2 were mixed and 
incubated for 30 min at room temperature.  The cells were rinsed with PBS and 4.2 ml of DMEM 
was added.  The solution of sets 1 and 2 was then added to the cells and incubated for 6 h in 
media lacking FBS.  After incubation, 5 ml of DMEM containing 5% FBS was added.  The cells 
were collected 24 h after transfection. For further applications, the cells were detached by 
incubation with 1 ml of warm Cell Stripper (Cellgro, Manassas, VA) for 10 min at 37°C.  The 
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cells were transferred to Falcon tubes and collected by centrifugation at 1200 rpm for 5 min at 
4°C.  The cells were rinsed with 1 ml of PBS, transferred to an eppendorf tube and centrifuged at 
5000 rpm for 5 min at 4°C.  Cell pellets were snap-frozen in liquid nitrogen and stored at -80°C.    
 
2.8       Immunoprecipitation 
 HeLa cell pellets were lysed for 1 h at 4°C with constant vortex on Lysis buffer B (50 
mM HEPES, 2.5 mM EGTA, 1 mM EDTA, 150 mM NaCl, 10% glycerol, 0.1% Tween 20, 50 
mM sodium fluoride, 10 mM sodium glycerophosphate, 5 mM sodium pyrophosphate, 1 mM 
orthovanadate, 1 mM DTT, 0.1 mM PMSF, and 2 µg/ml CLAP).  The lysates were sonicated 3 
times (duty cycle: 50; output 5) and centrifuged at 13,200 rpm for 10 min at 4°C.  The supernant 
was stored for protein quantification and immunoprecipitation. The protein concentration was 
determined by Bradford assay.  The immunoprecipitations were performed utilizing 500 µg of 
total cell extracts.  Lysis buffer B was added to a final volume of 500 µl.  One µl of anti-Xpress 
antibody (0.5 mg/ml, Invitrogen, Carlsbad, CA) was then added to the reaction and was 
incubated in a 360° rotator at 4°C for 14 h.  The immunoprecipitations were performed with the 
anti-Xpress antibody to pull-down the transfected caspase-3, while endogenous caspase-3 is 
unaffected.  The mixture was then incubated with 30 µl G-Agarose beads (Invitrogen, Carlsbad, 
CA) for 1 h at 4°C.  The beads were washed with 4 times with 700 µl of Lysis buffer B.  The 
beads were resuspended in 20 µl of 2x SDS loading buffer, and boiled for 5 min at 100°C.   
 
 
2.9       Bradford assays 
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 Bio-rad protein assay dye reagent 5x was diluted to 1x (Bio-Rad, Hercules, CA).  The 
dye was then added to standards of 0, 2, 4, 6, 8, and 10 µg BSA to a total volume of 1 ml and the 
absorbance was taken and used to plot a standard curve for protein quantification.  The curve 
was then used to estimate the protein concentration of lysates after adding 1 µL of the lysate to 
999 µL of Bradford dye 1x and taking the absorbance of the solution. 
 
2.10      Immunoblots 
The polypeptides were separated onto a 12% acrylamide gel at 150 V for 90 min.  The 
proteins were transferred to Protran Nitrocellulose Blotting Membranes (0.20 µm, Whatman, 
USA) for 70 min at 100 V on transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 20% 
Methanol).  The membranes were then blocked with 5% milk in TBS (10 mM Tris-HCl, 150 mM 
NaCl, and 0.05% Tween at pH=7.6).    The membranes were incubated with anti-Xpress primary 
antibody (1:4000, Invitrogen, Carlsbad, CA) to detect caspase-3 (36 kDa), and  with anti-HSP27 
polyclonal antibody (1:2000, Assay Designs, Ann Arbor, MI) to detect Hsp27 (27 kDa) for 14 h 
at 4°C.  The membranes were then incubated with horseradish peroxidase conjugated secondary 
antibodies; anti-mouse for anti-Xpress antibody (1:4000, GE, Piscataway, NJ) and anti-rabbit 
antibody for anti HSP27 antibody (1:2000, GE, Piscataway, NJ).  Proteins were visualized by 
autoradiography (Amersham Pittsburgh, PA).     
 
2.11     In vitro kinase assay 
 Immunoprecipitation with the anti-PKCδ antibodies were carried out as previously 
described (Regulation of monocyte apoptosis by the protein kinase C δ-dependent 
phosphorylation of caspase-3) [58].  After immunoprecipitation, in vitro kinase assays were 
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performed by incubating protein A-loaded beads for 1 h at 37°C in the presence of 20 µl kinase 
assay buffer (25 mM Hepes pH 7.3, 10 mM MnCl2, 1 mM MgCl2, 1 mM DTT) containing 5 mCi 
of {γ32P} ATP (Perkin Elmer, Boston, MA), 0.5 mM ATP.  To each reaction, 5 mg of histone 
H2B (Boehringer Mannheim, Roche, Indianapolis, IN) was added as exogenous substrate.  
Reactions were stopped by the addition of 10 ml of 5X Laemmli buffer.  Samples were boiled for 
5 min and loaded onto a SDS-PAGE.  The membrane was blotted with anti-PKCδ antibody to 
ensure equal loading. 
 
2.12    Caspase-3 activity assays: 
 Caspase-9 was added to fifty ng of recombinant caspase-3 in 2x reaction buffer with 2 
µg/ml of DTT and PMSF for 30 min, 1 h, and 2 h.  The activity of caspase-3 was measured at 
each time point by addition of the DEVD-AFC substrate, which upon cleavage by active 
caspase-3 releases AFC.  Released AFC were measured using a 15 Cytofluor 400 fluorimeter 
(Filters: excitation 400 nm, emission 508 nm; Perspective Co.,Framingham, MA).  In addition, 
SDS-PAGE gels were run with the activated samples and immunoblotted with anti-caspase-3 
antibodies to detect for the progression of caspase-3 proteolytic cleavage and activation.   
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Chapter 3 
Results 
3.1       Approach 
Due to its importance in cell death, caspase-3 is expected to be highly regulated in order 
to prevent unwanted activation of the apoptotic cascade.   Caspase-3 exists in the cell in an 
inactive state and is regulated by proteolysis.  We investigated here the molecular mechanisms of 
PKCδ-dependent phosphorylation of caspase-3 to identify the sites that are phosphorylated and 
to characterize the role of phosphorylation in the regulation of caspase-3 activity.  
Posttranslational modifications like phosphorylation have been shown to regulate many proteins 
involved in cell cycle control such as cyclin-dependent kinases, retinoblastoma protein, and p53 
[68].  The first evidence that caspases can be regulated by phosphorylation was provided by the 
ability of the kinase Akt to phosphorylate pro-caspase-9 at Ser196, inhibiting its protease activity 
[53].  Since then, other kinases such as Erk and p38 have also been shown to phosphorylate 
caspases [54] [55].  Interestingly, most of those phosphorylations results in an inhibition of 
caspase activity.  Here we show for the first time evidence that phosphorylation can also 
positively regulate caspase activity. 
The possible PKCδ phosphorylation sites in caspase-3 were narrowed by a combination 
of in silico mapping, mass spectroscopy, and evolutionary conservation.  In silico mapping using 
NetPhos and Scansite Motif Scan predicted 11 potential target sites of PKCδ (Fig. 3a).  Of these 
sites, 8 were conserved through evolution (Fig 3b).  Analysis by mass spectroscopy confirmed 
seven of them as real phosphorylation sites (Fig. 3c).  The seven predicted PKCδ-dependent 
phosphorylation sites were Ser12, Ser32, Ser36, Ser58, Thr59, Thr67, and Thr77.   
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Figure 3: Prediction of PKCδ phosphorylation sites in caspase-3 
(a) In silico mapping predicted 11 possible target sites of PKCδ (shown in green or gold).  (b) Of these 
sites, only 8 were conserved throughout evolution (shown with star).  (c) Analysis by mass spectroscopy 
further narrowed the list of potential phosphorylation sites to just 7 sites (shown by gold bar). 
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3.2       Generation of phospho-mimicking caspase-3 mutants 
 
            To map the sites phosphorylated by PKCδ, we created caspase-3 phospho-mimicking 
mutants by site directed mutagenesis.  This approach has been extensively used to understand the 
functions of phosphoproteins [53].  The predicted Ser or Thr amino acids were mutated to Gly or 
Ala, to mimic no phosphorylation, or to Asp to mimic a phosphorylated amino acid, respectively.  
The point mutations were introduced on caspase-3 wild-type in a PQE31 vector by amplification 
of the template DNA with mutagenic primers.  Using this approach, we created clones with 
single point mutations of each of the predicted phosphorylation sites.  We also created clones 
with different combinations of the point mutations in order to gain insights into the mechanism 
and regulation of the multiple PKCδ-dependent phosphorylations involved in promoting the 
activation of caspase-3. The full list of mutants is found in Appendix: Table 2.  These mutants 
were employed in both in vivo and in vitro analyses to determine the role of each particular 
phosphorylation site on the biological activity of caspase-3.  Figure 4 will serve as a guide for the 
experimental scheme that will be discussed in detail later.   We focus in this paper on the Ser12 
site of caspase-3 because it is the only predicted phosphorylation site present in the prodomain. 
This is especially relevant since, unlike the function of the initiator caspases’ long prodomains to 
facilitate protein-protein binding for autocatalytic processing, the exact function of the shorter 
prodomain in effector caspases has yet to be determined.  Although there is evidence that the 
prodomain serves as an inhibitory element in caspase-3, the mechanism of this regulation is 
unknown [29].  Identification of a possible phosphorylation site in the prodomain of caspase-3 
would serve to elucidate a previously unknown mechanism of prodomain regulation of caspase-3 
activity. 
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      (A)                                     (B) 
 
Figure 4: Experimental Scheme 
(A) In vitro approach. Nickel column chromatography for protein purification followed by in vitro kinase 
assays of recombinant proteins. (B) In vivo approach.  Cloning into mammalian expression vector for 
transfections 
 
25 
 
3.3      Purification of recombinant human caspase-3 phospho-mutant proteins 
 
In order to determine the effect of the mutants on caspase-3 activity in vitro, we first 
purified the recombinant protein from E. coli cells.  Recombinant caspase-3 protein was purified 
from lysed bacteria using affinity column chromatography for the 6X Histidine tag on the PQE31 
vector (as described in Materials and Methods).   The proteins were eluted using a discontinuous 
imidazol gradient and run on a SDS-PAGE gel.  The gel was stained with coomassie and 
caspase-3 was found eluting at a concentration of 100 mM imidazole (Fig. 5).  The 100 mM 
imidazole fractions that contained caspase-3 were then dialyzed and used for subsequent 
experiments.   
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Figure 5: Protein Purification of caspase-3-S12G mutant in PQE31M 
SDS-PAGE gel run of selected fractions from purification of caspase-3-S12G using Ni2+ - NTA affinity 
column chromatography.  To= before IPTG. T30=after IPTG.  Flow, sonication, and washing are washings 
done before elution.  Elution was done with discontinuous imidazol gradient.  Gel was stained with 
coomassie. 
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3.4      Ser12 is important for PKCδ-dependent phosphorylation in recombinant caspase-3 
 
To determine the effects of the mutations on the phosphorylation of caspase-3 by PKCδ, 
in vitro kinase assays were performed.  In vitro kinase assays were performed with wild type 
caspase-3, caspase-3-S12G, or caspase-3-S12D recombinant proteins in the presence of PKCδ 
and [γ32P] ATP.  The in vitro kinase assays were resolved by SDS-PAGE and the gels were 
stained with silver to ensure equal loading.  We found that wild type caspase-3 is phosphorylated 
(Fig. 6 lane 2).  In contrast, in caspase-3-S12G mutants, the phosphorylation was completely 
abolished (Fig. 6 lane 3).  Notably, we found that in the caspase-3-S12D mutants, the 
phosphorylation increases by over 5-fold when compared to the wild type (Fig. 6 Lane 4).  These 
results suggest that phosphorylation on Ser12 is essential for PKCδ phosphorylation and that this 
phosphorylation promotes phosphorylation of additional sites.   
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Figure 6: Caspase-3-S12D is phosphorylated in vitro 
Human purified recombinant wild type caspase-3, caspase-3-S12G, and caspase-3-S12D were 
subjected to in vitro kinase assay in the presence of PKCδ. A reaction containing boiled PKCδ was 
utilized as a control.   Phosphorylated kinase products were resolved by SDS-PAGE and stained with 
silver staining. Phospholabeled proteins were visualized by autoradiography.   
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3.5       Expression of human caspase-3 phospho-mutants in mammalian cells 
 
Since Ser12 on caspase-3 showed an important role in the phosphorylation of caspase-3 
in vitro, we next investigated its biological function in mammalian cells.  For this purpose, we 
cloned the caspase-3 phospho-mimicking mutants into the pcDNA 4/HIS Max Xpress vector 
(Scheme on Fig. 4b).  PCR was first performed on the mutant caspase-3 in PQE31M vector to 
introduce the appropriate restriction sites, EcoRI and BamHI, for correct insertion into the 
pcDNA 4/HIS Max Xpress vector.  PCR reactions also allowed the formation of the caspase-3 
prop17 clones lacking the p12 C-terminal domain, allowing it to mimic caspase-3 after the first 
proteolytic cleavage (see Appendix: Table 1 for different primer combinations).  Full-length 
caspase-3 mutants ran at 850 bp while prop17 mutants (which lack the p12 domain) ran at 500 
bp (Fig. 7a).  The PCR products were then ligated into the p-ENTR/D-TOPO vector.  The 
pENTR/D-TOPO vector is used for efficient ligation of small inserts with only one sticky end by 
using the topoisomerase linked to the vector.  The vector is used as an intermediate step for the 
cloning into the pcDNA 4/HIS Max Xpress vector.  The DNA was then transformed into TOP10 
or DH5α cells, purified by Spin Miniprep, and digested with BamHI and EcoRI to test for the 
presence of the caspase-3 insert.  Potential positive clones were sent for sequencing to ensure 
that no additional mutations had been introduced.  Once the mutants were verified, restriction 
digestion was performed and the linearized insert was excised, purified by DNA extraction, and 
quantified versus the vector (Fig. 7b).  The purified insert was then ligated to the pcDNA 4/His 
Max Xpress mammalian expression vector utilizing the T4 ligase.  The ligation product was 
transformed into Top10 competent cells and the colonies were grown in LB agar plates 
containing ampicillin.  The DNA was purified and screened by restriction digestion, with 
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positive clones showing a band at 850 bp being sent for sequencing (Fig. 7c).  The pcDNA 4/His 
Max Xpress mammalian expression vector was subsequently used for mutants intended for 
transfection into mammalian cells.   
  
 
 
Figure 7: Cloning of caspase-3-S12G mutant into the mammalian expression vector 
 
(A) Quantification of PCR products using different amounts of standards from previous minipreps.  (B) 
Quantification of DNA caspase-3-S12G insert and pcDNA 4/His Max Xpress Vector for ligation: (1) One 
µL zipped Xpress vector, (2) 2 µL zipped Xpress vector, (3) 3 µL of insert, (4) 3 µL of insert (C) 
Screening for positive clones after ligation into the mammalian expression vector by cutting with BamHI 
and EcoRI.  Run on a 1% agarose gel.  Lanes 2-7 show positive clones. 
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3.6      Caspase-3 is phosphorylated on Ser12 in HeLa cells 
  
 Since we found that Ser12 is phosphorylated by PKCδ in vitro, the next step was to 
determine the phosphorylation in vivo.  In order to determine the effects of the caspase-3 mutants 
on PKCδ-dependent phosphorylation in vivo, wild-type caspase-3, caspase-3-S12G, and caspase-
3-S12D mutants were transiently transfected into HeLa cells.  Twenty-fours after transfection, 
the cells were lysed and the caspase-3 proteins were immunoprecipitated with an antibody 
specific for the Xpress epitope.  An IgG antibody was used as a control for the 
immunoprecipitation.  The immunoprecipitates were then subject to an in vitro kinase assay.  
The IgG control had no caspase-3 and thus no phosphorylation, as expected (Fig. 8 lane 1).  We 
found that wild-type caspase-3 is phosphorylated in HeLa cells (Fig. 8 lane 2) while the caspase-
3-S12G mutants are not (Fig. 8 lane 3), indicating that Ser12 is a target for PKCδ in vivo.  The 
caspase-3-S12D mutant shows hyperphosphorylation on an order of 10X the magnitude of the 
wild type caspase-3 (Fig. 8 lane 4).  This data suggests that phosphorylation of Ser12 promotes 
phosphorylation of additional phosphorylation sites.  Collectively, these results are in agreement 
with the results obtained using the purified recombinant proteins.  This data suggests that 
phosphorylation of Ser12 plays an important role in the PKCδ-dependent phosphorylation of 
caspase-3.   
 
3.7       Phosphorylation of Ser12 promotes caspase-3 activity 
 We studied the effects of the phospho-mimicking mutants on caspase-3 activity in order 
to determine the role of caspase-3 phosphorylation on its protease activity.  DEVD-AFC caspase-  
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Figure 8: Ser12 on caspase-3 is phosphorylated in HeLa cells 
 Immunoprecipitated wild type caspase-3, caspase-3-S12G, and caspase-3-S12D mutants were subjected 
to in vitro kinase assay in the presence of PKCδ cofactors.  Phosphorylated kinase products were resolved 
by SDS-PAGE and the phospholabeled proteins were visualized by autoradiography. The membrane was 
also immunoblotted with anti-Xpress antibody to ensure equal loading of caspase-3.   
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3 activity assays were employed using the recombinant wild-type caspase-3 and caspase-3-S12D 
mutants that were generated.  Purified wild type caspase-3 and caspase-3-S12D mutant proteins 
were mixed with purified, active caspase-9 and the mixture was incubated for 0, 0.5, 1, and 2 
hours at 370C to promote the first catalytic cleavage of caspase-3.  Half of the reaction was used 
to determine caspase-3 activity while the other half was run on an acrylamide gel to determine 
caspase-3 cleavage.  The activity of caspase-3 was measured by the addition of the DEVD-AFC 
substrate.   Cleavage of the DEVD-AFC substrate by active caspase-3 causes the release of AFC, 
which in turn emits a yellow-green fluorescence.  Therefore, the fluorescence of the reaction is 
correlated with the level of caspase-3 activation.  The average fluorescence of the wild type 
caspase-3 assays was 4627 nM AFC/min/µg protein at 1 hour and 7847 nM AFC/min/µg protein 
at 2 hours (Fig. 9a).  The average fluorescence of the Caspase-3-S12D mutant assays was 8897 
nM AFC/min/µg protein at 1 h and 10,287 nM AFC/min/µg protein at 2 h.  The activity of the 
caspase-3-S12D mutants was thus 1.9 times greater than wild type caspase-3 activity at 1 h and 
1.3 times greater at 2 h, both being statistically significant.  This suggests that phosphorylation of 
Ser12 plays a key role in modulating caspase-3 proteolytic activity and that phosphorylation of 
the site increases caspase-3 activity. 
  Next, we studied the effect of phosphorylation on the catalytic cleavage of caspase-3.  
Caspase-3 undergoes two sequential cleavages before forming the active tetramer.  The first 
cleavage removes the p12 C-terminal domain, forming prop17, while the second, autocatalytic 
cleavage results in cleavage between the p17 and the prodomain.  Importantly, the first cleavage 
is caspase-9 dependent while the second cleavage is caspase-3 dependent. We determined the 
effect of Ser12 phosphorylation in the generation of these peptides by western blot analysis. The 
activity assay reactions of wild type caspase-3 and caspase-3-S12D were resolved by SDS-
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PAGE and probed with anti-caspase-3 antibodies.  Analysis of the blots reveal that the first 
cleavage of caspase-3 to the prop17 form occurred by 30 min in both wild-type caspase-3 and 
caspase-3-S12D (Fig. 9b).  At 1 hour, the second autocatalytic cleavage has already occurred in 
the caspase-3-S12D mutants, as seen by the p17 band at 17 kDa and lack of the prop17 band at 
22 kDa. The second autocatalytic cleavage does not occur in the wild-type caspase-3 until 2 
hours.    Caspase-3-S12D mutants show a faster kinetics of cleavage, and thus faster activation 
when compared to wild-type caspase-3.   The cleavage assays and the caspase-3 activity assays 
together demonstrate that phosphorylation of Ser12 increases the apoptotic ability of caspase-3 
and results in a faster second, autocatalytic cleavage during the processing of the active tetramer.   
These observations detail a novel mechanism of caspase-3 activation.  While there are other 
examples of caspases being regulated by phosphorylation (ERK and Akt phosphorylation of 
caspase-9 and p38 phosphorylation of caspase-3 and caspase-8), these posttranslational 
modifications are all inhibitory and prevent proteolytic cleavage and activation of the caspases 
[53] [54] [55].  PKCδ-dependent phosphorylation of Ser12 on the other hand promotes the 
second autocatalytic cleavage of caspase-3 and promotes activation. 
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Figure 9: Phosphorylation of Ser12 promotes caspase-3 activity 
(A) Recombinant wild type caspase-3 (white) and caspase-3-S12D (black) were activated by incubation 
with recombinant caspase-9 (40 U) for 0.5, 1, and 2 hours at 37˚C. Caspase-3 activity was monitored by 
cleavage of DEVD-AFC and release of fluorescent AFC (fluorescence units) over time.  The higher 
activity of caspase-3-S12D mutants were statistically significant compared to wild-type at 1hour (P 
<0.001) and 2 hours (P<0.05), as indicated by asterisk. (B) Time points from the caspase-3 activity assay 
were run on a SDS-PAGE gel and immunoblots were done with anti-caspase-3 antibodies. 
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 We have demonstrated that caspase-3 can be phosphorylated at Ser12 by PKCδ and that 
this phosphorylation causes an increase in its apoptotic ability.  In addition, this data suggests 
that this phosphorylation is important in regulating additional phosphorylation sites in caspase-3, 
evidenced by a lack of phosphorylation of the caspase-3 when the site was mutated to a glycine 
and hyperphosphorylation when the site was mutated to aspartic acid.  Additional experiments 
performed in the lab have confirmed an important role of Ser12 on apoptosis. MCF-7 cells 
transiently transfected with caspase-3-S12G mutant plasmids show a 30% decrease in apoptosis 
after treatment with etoposide when compared to cells transfected with wild type caspase-3.  
These results begin to unravel the complex mechanism behind PKCδ activation of caspase-3.  
Other mutants, both single and multi-point are being tested as well in order to determine the roles 
of other phosphorylation sites on the activity of caspase-3.  In our current model, PKCδ 
phosphorylates caspase-3 at Ser12 and the phosphorylation of this site is important for the 
execution of cell death by promoting caspase-3 activity.   
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Chapter 4 
Discussion 
 
 Caspase-3 plays an important role in programmed cell death by cleaving essential cell 
machinery to promote cellular fragmentation into apoptotic bodies that can then be degraded by 
phagosomes [1] [10 [21] [32].  Since it lies in such a crucial intersection of the apoptotic 
cascade, caspase-3 is highly regulated by many other proteins.  We studied the regulation of 
caspase-3 by one of these proteins, the kinase PKCδ.  All previously known regulatory 
mechanisms that result in phosphorylation of caspases are inhibitory and prevent proteolytic 
cleavage of the pro-caspases [53] [54] [55].  PKCδ-dependent phosphorylation of caspase-3 is a 
novel posttranslational modification because phosphorylation of caspase-3 activates the protein.  
For this reason, we analyzed the molecular mechanisms behind PKCδ phosphorylation of 
caspase-3.   
We began by identifying seven potential phosphorylation sites in caspase-3.  We then 
proceeded to create phospho-mimicking mutants in order to determine the relative importance of 
each of those sites on caspase-3 regulation and enzyme activity.  The phospho-mutants were 
employed in both in vitro and in vivo analyses.  In the in vitro approach, recombinant caspase-3 
proteins were affinity purified and subjected to in vitro kinase assays in the presence of PKCδ.  
In the in vivo approach, we cloned the mutants into a mammalian expression vector and 
transfected them into HeLa cells.  This approach allowed us to observe the phosphorylation and 
activity of caspase-3 in different setting.  We focused on the Ser12 site since it is the only one 
predicted phosphorylation sites to be found on the prodomain of caspase-3.  This is especially 
important because, unlike the protein binding functions of the long prodomains of initiator 
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caspases, the functions of the short prodomains in effector caspases have remained largely 
unknown [20].   
We found that the Ser12 site in the prodomain of caspase-3 is a phosphorylation site that 
serves a regulatory role in caspase-3 activation.  Phosphorylation of the site promotes caspase-3 
activation by accelerating the second autocatalytic cleavage during the formation of the active 
heterotetramer.  This interaction provides a second novel aspect of PKCδ-dependent 
phosphorylation of caspase-3.  We have demonstrated a specific role of the prodomain of 
caspase-3 in regulating its activation: phosphorylation of the Ser12 residue in the prodomain can 
increase caspase-3 activity.  The functions of the caspase-3 prodomain had remained largely 
unknown until recently.  It had previously been shown that removal of the prodomain results in 
spontaneous activation, implicating the prodomain as an inhibitory regulator [29].  In addition, it 
was recently found that caspase-3 inhibition by hsp27 occurs via binding of hsp27 to the 
prodomain of caspase-3, inhibiting the first proteolytic cleavage required for activation [57].  
Our results identify an additional role of the prodomain in caspase-3 regulation.   
 Another interesting feature about the Ser12 phosphorylation site is that phosphorylation 
at the site appears to promote phosphorylation at additional sites, as seen by the 
hyperphosphorylation of caspase-3-S12D mutants in the in vitro kinase assays. This implicates 
Ser12 as a crucial regulatory site for PKCδ-dependent phosphorylation.  Phosphorylation of 
Ser12 may change the conformation of the caspase-3 domains such that the remaining 
phosphorylation sites in the p12 domain are more accessible and can now be phosphorylated as 
well.  However, without a crystal structure of the prodomain of caspase-3, it will be difficult to 
establish a definitive structural model for Ser12 regulation of the additional phosphorylation 
sites.    
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 For future direction, the relative importance of the remaining phosphorylation sites on 
caspase-3 activation must also by determined by using the same in vitro and in vivo analyses 
with different combinations of mutants.  Using the different combinations of single and multi-
point mutants which have already been cloned, we will be able to further elucidate the 
mechanisms of PKCδ activation of caspase-3.  PKCδ-dependent phosphorylation of caspase-3 
has been shown to be a novel method of caspase regulation because it both promotes the 
apoptotic ability of caspase-3 and does so by interacting with its prodomain.  Analysis of 
different types of cancers in 2003 revealed that there is little correlation between cancerous cells 
and the total amount of caspase-3 in the cell, indicating that posttranslational modifications of 
caspases play an important role in clinical abnormalities [41].  Further analysis of the mechanism 
will detail crucial sites in the caspase-3 protein that could then be potentially applied as cancer 
markers. 
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Appendix 
 
 
Table 1: Primer and Restriction Enzymes Guide 
 
 
 
 
 
 
 
Primer Number Sequence 
PAO 120 5'-CACCGGATCCATGGAGAACACTGAAAAC-3' 
PAO 147 5'-CACCGAGCTCGCCACCATGGAGAACACTGAAAACTCA-3' 
PAO 148 5'-CTCGAGGACCGGTTTGTGATAAAAATAGAGTTC-3' 
PAO 188 5'-GAATTCGTCTGTCTCAATGCCACAGTCCAGTTC-3' 
PAO 189 5'-GAATTCTTAGTGATAAAAATAGAGTTC-3' 
PAO 289 5'-GTCGACTTAGTCTGTCTCAATGCCACAGTCCAGTTC-3' 
 
 
 
 
 Primers    
Construct  Forward Reverse Restriction Enzymes 
Intermediate 
Vector Final Vector 
Full Length PAO 147 
PAO 
148 
SacI AgeI 
pENTR™/D-
TOPO®   
pDs-RED N1 
Full Length PAO 120 
PAO 
189 
BamH1 EcoRI 
pENTR™/D-
TOPO®   
pcDNA 4/His 
Max Xpress  
Prop17 PAO 120 
PAO 
289 
SalI BamH1 
pENTR™/D-
TOPO®   
PQE31M 
Prop17 PAO 120 
PAO 
188 BamHI EcoRI 
pENTR™/D-
TOPO®   
pcDNA 4/His 
Max Xpress  
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Table 2: List of Clones 
 
 
 
Construct 
Name Clone Name AB Number Description 
Bacterial 
Host 
HK-1 S12G, S36A -FL AB 540 
Full length caspase-3 mutant 
in PQE31M M15 
HK-2 S12G, T59A -FL AB 541 
Full length caspase-3 mutant 
in PQE31M M15 
HK-3 
S12G, S36A, T59A -
FL AB 535 
Full length caspase-3 mutant 
in PQE31M M15 
HK-4 S36A, T59A -FL AB 536 
Full length caspase-3 mutant 
in PQE31M M15 
HK-5 
S12G, S36A, T59A, 
T67A, T77A- FL AB 560 
Full length caspase-3 mutant 
in PQE31M M15 
HK-6 
S12D, S36D, T59D- 
FL AB 537 
Full length caspase-3 mutant 
in PQE31M M15 
HK-7 S12D, S36D- FL AB 653 
Full length caspase-3 mutant 
in PQE31M M15 
HK-8 S36D, T59D- FL AB 562 
Full length caspase-3 mutant 
in PQE31M M15 
HK-9 S12D, T59D- FL AB 564 
Full length caspase-3 mutant 
in PQE31M M15 
HK-10 T77A FL AB 561 
Full length caspase-3 mutant 
in PQE31M M15 
HK-11 
S12G, S32A, S36A, 
S58A, T59A, T67A, 
T77A- FL NA 
Full length caspase-3 mutant 
in PQE31M Top10 
HK-12 
S12D, S32D, S36D, 
S58D, T59D, T67D, 
T77D –FL NA 
Full length caspase-3 mutant 
in PQE31M Top10 
HK-13 
S12D, S36D, T59D, 
T67D, T77D –FL NA 
Full length caspase-3 mutant 
in PQE31M Top10 
HK-14 S32A-FL NA 
Full length caspase-3 mutant 
in PQE31M Top10 
HK-15 S32D-FL NA 
Full length caspase-3 mutant 
in PQE31M Top10 
HK-16 S58A-FL NA 
Full length caspase-3 mutant 
in PQE31M Top10 
HK-17 S58D-FL NA 
Full length caspase-3 mutant 
in PQE31M Top10 
HK-18 S36D-FL NA Full length caspase-3 mutant Top10 
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in PDSRED2-N1 
HK-19 S12D-FL NA 
Full length caspase-3 mutant 
in PDSRED2-N1 Top10 
HK-21 S10A-FL NA 
Full length caspase-3 mutant 
in PENTR™/D-TOPO®  to 
clone into PDSRED2-N1 Top10 
HK-22 S10A-FL NA 
Full length caspase-3 mutant 
in PENTR™/D-TOPO®  to 
clone into PDSRED2-N1 Top10 
HK-23 S10A-FL NA 
Full length caspase-3 mutant 
in PDSRED2-N1 Top10 
HK-24 S12G-FL NA 
Full length caspase-3 mutant 
in PENTR™/D-TOPO®  to 
clone into PcDNA 4/His 
Max Xpress vector Top10 
HK-25 S12D-FL NA 
Full length caspase-3 mutant 
in PENTR™/D-TOPO®  to 
clone into PcDNA 4/His 
Max Xpress vector Top10 
HK-27 S12D- prop17 AB 583 
Prop17 caspase-3 mutant in 
PENTR™/D-TOPO®  to 
clone into PcDNA 4/His 
Max Xpress vector DH5a 
HK-28 S12G-prop17 AB 582 
Prop17 caspase-3 mutant in 
PENTR™/D-TOPO®  to 
clone into PcDNA 4/His 
Max Xpress vector DH5a 
HK-29 
S12G, S32A, S36A, 
S58A, T59A, T67A, 
T77A- FL NA 
Full length caspase-3 mutant 
in PQE31 DH5a 
HK-30 S12G-FL AB 580 
Full length caspase-3 mutant 
in PcDNA 4/His Max 
Xpress vector DH5a 
HK-31 S12D-FL AB 581 
Full length caspase-3 mutant 
in PcDNA 4/His Max 
Xpress vector DH5a 
HK-32 S12D- prop17 AB 583 
Prop17 caspase-3 mutant in 
PcDNA 4/His Max Xpress 
vector DH5a 
HK-33 S12G- prop17 AB 582 
Prop17 caspase-3 mutant in 
PcDNA 4/His Max Xpress 
vector DH5a 
Prop17 7th 
S12G, S32A, S36A, 
S58A, T59A, T67A, 
T77A- prop17 NA 
Prop17 caspase-3 mutant in 
PQE31M DH5a 
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Prop17 S12G S12G- prop17 NA 
Prop17 caspase-3 mutant in 
PQE31M DH5a 
Prop17 7th-X 
S12G, S32A, S36A, 
S58A, T59A, T67A, 
T77A- prop17 NA 
Prop17 caspase-3 mutant in 
PENTR™/D-TOPO®  to 
clone into PcDNA 4/His 
Max Xpress vector NA 
Prop17 5h-X 
S12G, S36A, T59A, 
T67A, T77A - prop17 NA 
Prop17 caspase-3 mutant in 
PENTR™/D-TOPO®  to 
clone into PcDNA 4/His 
Max Xpress vector NA 
OVYM 1-
3/AB542 S36D-FL AB 542* 
Full length caspase-3 mutant 
in PcDNA 4/His Max 
Xpress vector DH5a 
OVYM 2/ 
AB487 S36A-FL AB 487* 
Full length caspase-3 mutant 
in PcDNA 4/His Max 
Xpress vector DH5a 
OVYM 3-
5/AB563 S12D, S36D -FL AB 563* 
Full length caspase-3 mutant 
in PcDNA 4/His Max 
Xpress vector DH5a 
OVYM 4/ 
AB540 S12G, S36A -FL AB 540* 
Full length caspase-3 mutant 
in PcDNA 4/His Max 
Xpress vector DH5a 
* Mutants in PQE31M vector before being clones into Xpress.  New AB numbers not yet designated 
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Table 3: Construct Maps 
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